Author

G. Stewart-Jones

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Research Focus:cell type annotation· 2 Assay:multiome· 2 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Carfi· 3 shared A. Nasir· 2 shared B. Whitener· 2 shared B. Ying· 2 shared D. K. Edwards· 2 shared D. Lee· 2 shared G.-Y. Chuang· 2 shared J. I. Moliva· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Carfi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

A. W. Freyn, C. Atyeo, P. L. Earl, J. L. Americo, G.-Y. Chuang, H. Natarajan, T. R. Frey, J. Gall, J. I. Moliva, R. Hunegnaw, G. Asthagiri Arunkumar, C. Ogega, A. Nasir, H. Bennett, J. Johnson, , B. Moss

This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.

bioRxiv · Dec 17, 2022 · PreprintImmunology

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains

G. Stewart-Jones, S. M. Elbashir, K. Wu, D. Lee, I. Renzi, B. Ying, M. Koch, C. E. Sein, A. Choi, B. Whitener, D. Garcia-Dominguez, C. Henry, A. Woods, L. Ma, D. Montes Berrueta, , A. Carfi

The paper develops and evaluates an mRNA vaccine, mRNA-1283, encoding SARS-CoV-2 spike N-terminal and receptor-binding domains, showing improved immunogenicity and protection against multiple variants in mice.

bioRxiv · Oct 7, 2022 · PreprintImmunology

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant

S. M. Scheaffer, D. Lee, B. Whitener, B. Ying, K. Wu, H. Jani, P. Martin, N. J. Amato, L. E. Avena, D. M. Berrueta, S. D. Schmidt, S. O'Dell, A. Nasir, G.-Y. Chuang, G. Stewart-Jones, , M. S. Diamond

This study evaluates bivalent SARS-CoV-2 mRNA vaccines and finds they induce broader neutralizing antibodies and better protection against BA.5 Omicron compared to monovalent vaccines.

bioRxiv · Sep 12, 2022 · PreprintMicrobiology

Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques

W. B. Williams, R. Meyerhoff, R. J. Edwards, H. Li, N. Nicely, R. Henderson, Y. Zhou, K. Janowska, K. Mansouri, K. Manne, V. Stalls, A. L. Hsu, M. J. Borgnia, G. Stewart-Jones, M. S. Lee, , B. F. Haynes

The paper identifies Fab-dimerized glycan-reactive antibodies in HIV-infected macaques and HIV-naïve humans that neutralize HIV-1 and can be elicited by vaccination.

bioRxiv · Jun 30, 2020 · PreprintImmunology

A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone

B. Zhang, C. W. Chao, Y. Tsybovsky, O. M. Abiona, G. B. Hutchinson, J. I. Moliva, A. S. Olia, A. Pegu, E. Phung, G. Stewart-Jones, R. Verardi, L. Wang, S. Wang, A. Werner, E. S. Yang, , P. D. Kwong

This paper develops a nanoparticle platform for displaying trimeric antigens, showing that SARS-CoV-2 spike-LuS nanoparticles induce 25-fold higher neutralizing responses than spike alone.

bioRxiv · Jun 11, 2020Immunology